CAPTRUST Financial Advisors’s ImmunityBio IBRX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$187K	Sell	21,411 -40,181	-65%	-$304K	﹤0.01%	2901
2026 Q1	$472K	Buy	61,592 +5,195	+9%	+$35.6K	﹤0.01%	2068
2025 Q4	$112K	Buy	56,397 +249	+0.4%	+$564	﹤0.01%	2599
2025 Q3	$138K	Buy	56,148 +42,762	+319%	+$110K	﹤0.01%	2478
2025 Q2	$35.3K	Buy	13,386 +2,645	+25%	+$7.11K	﹤0.01%	2454
2025 Q1	$32.3K	Buy	+10,741	New	+$32.6K	﹤0.01%	2304
2024 Q4	–	Sell	-11,073	Closed	-$41.2K	–	2340
2024 Q3	$41.2K	Buy	+11,073	New	+$51.2K	﹤0.01%	2242
2022 Q3	–	Sell	-1,920	Closed	-$7K	–	2984
2022 Q2	$7K	Hold	1,920	–	–	﹤0.01%	3925
2022 Q1	$11K	Hold	1,920	–	–	﹤0.01%	3747
2021 Q4	$12K	Hold	1,920	–	–	﹤0.01%	3612
2021 Q3	$19K	Hold	1,920	–	–	﹤0.01%	3198
2021 Q2	$27K	Hold	1,920	–	–	﹤0.01%	2907
2021 Q1	$46K	Buy	+1,920	New	+$49.8K	﹤0.01%	2478

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CAPTRUST Financial Advisors's IBRX Position: Q2 2026 in Review

CAPTRUST Financial Advisors reduced its ImmunityBio (IBRX) stake by 65% in Q2 2026, selling an estimated $304K and leaving 21,411 shares worth $187K. The position accounts for ﹤0.01% of the portfolio, ranked #2901.

CAPTRUST Financial Advisors first reported a position in IBRX in Q1 2021 and has held it in 13 quarters since. The position peaked at $472K in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

CAPTRUST Financial Advisors held 21,411 shares of ImmunityBio worth $187K as of Q2 2026.
CAPTRUST Financial Advisors sold 40,181 ImmunityBio shares in Q2 2026, an estimated $304K.
ImmunityBio made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2901 holding.
CAPTRUST Financial Advisors first reported a position in ImmunityBio in Q1 2021 and has held it in 13 quarters since.
CAPTRUST Financial Advisors's ImmunityBio position peaked at $472K in Q1 2026.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.